Zobrazeno 1 - 10
of 413
pro vyhledávání: '"Verbaanderd C"'
Autor:
Zarkavelis, G., Amylidi, A.L., Verbaanderd, C., Cherny, N.I., Metaxas, Y., de Vries, E.G.E., Zygoura, P., Amaral, T., Jordan, K., Strijbos, M., Dafni, U., Latino, N., Galotti, M., Lordick, F., Giuliani, R., Pignatti, F., Pentheroudakis, G.
Publikováno v:
In ESMO Open February 2023 8(1)
Autor:
Verbaanderd C; PhaRA Consulting, Antwerp, Belgium., Trullás Jimeno A; European Medicines Agency, Amsterdam, The Netherlands., Engelbergs J; Paul Ehrlich Institute, Langen, Germany., Zander H; Paul Ehrlich Institute, Langen, Germany., Reischl I; Austrian Agency for Health and Food Safety, Wien, Austria., Moreno Oliver A; Spanish Agency for Medicines and Health Care Products, Madrid, Spain., Vamvakas S; European Medicines Agency, Amsterdam, The Netherlands., Vleminckx C; European Medicines Agency, Amsterdam, The Netherlands., Bouygues C; European Medicines Agency, Amsterdam, The Netherlands., Girard T; European Medicines Agency, Amsterdam, The Netherlands., Day F; European Medicines Agency, Amsterdam, The Netherlands., Frias Z; European Medicines Agency, Amsterdam, The Netherlands.
Publikováno v:
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2023 Aug; Vol. 114 (2), pp. 316-324. Date of Electronic Publication: 2023 May 25.
Autor:
Simoens S; KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium., Abdallah K; KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium., Barbier L; KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium., Lacosta TB; KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium., Blonda A; KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium., Car E; KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium., Claessens Z; KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium., Desmet T; KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium., De Sutter E; KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium., Govaerts L; KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium., Janssens R; KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium., Lalova T; KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium.; KU Leuven Centre for IT & IP Law (CiTiP), Leuven, Belgium., Moorkens E; KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium., Saesen R; KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium.; European Organisation for Research and Treatment of Cancer, Brussels, Belgium., Schoefs E; KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium., Vandenplas Y; KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium., Van Overbeeke E; KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium., Verbaanderd C; KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium.; Anticancer Fund, Strombeek-Bever, Brussels, Belgium., Huys I; KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium.
Publikováno v:
Frontiers in pharmacology [Front Pharmacol] 2022 Sep 16; Vol. 13, pp. 960701. Date of Electronic Publication: 2022 Sep 16 (Print Publication: 2022).
Autor:
Mulder J; Dutch Medicines Evaluation Board, Utrecht, Netherlands., Verjans R; Lygature, Utrecht, Netherlands., Verbaanderd C; European Medicines Agency, Amsterdam, Netherlands.; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium., Pean E; European Medicines Agency, Amsterdam, Netherlands., Weemers J; Janssen Biologics BV, Leiden, Netherlands., Leufkens HGM; Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands., Pignatti F; European Medicines Agency, Amsterdam, Netherlands., de Boer A; Dutch Medicines Evaluation Board, Utrecht, Netherlands.; Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands., Voest EE; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, Netherlands.; Oncode Institute, Amsterdam, Netherlands., Stoyanova-Beninska VV; Dutch Medicines Evaluation Board, Utrecht, Netherlands., Pasmooij AMG; Dutch Medicines Evaluation Board, Utrecht, Netherlands.
Publikováno v:
Frontiers in medicine [Front Med (Lausanne)] 2021 Dec 09; Vol. 8, pp. 790782. Date of Electronic Publication: 2021 Dec 09 (Print Publication: 2021).
Autor:
Verbaanderd C; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium. ciska.verbaanderd@kuleuven.be.; Anticancer Fund, Strombeek-Bever, Belgium. ciska.verbaanderd@kuleuven.be., Rooman I; Anticancer Fund, Strombeek-Bever, Belgium.; Oncology Research Centre, Vrije Universiteit Brussel, Brussels, Belgium., Huys I; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Publikováno v:
Trials [Trials] 2021 May 04; Vol. 22 (1), pp. 322. Date of Electronic Publication: 2021 May 04.
Autor:
del Álamo, Marta1 (AUTHOR) marta.delalamo@ecrin.org, Lémeret, Sabrina1 (AUTHOR), Nieto, Cristina2 (AUTHOR), Pandya, Lara3 (AUTHOR), Hagen, Hans4 (AUTHOR), Walker, Saul5 (AUTHOR), Demotes, Jacques1 (AUTHOR)
Publikováno v:
Trials. 10/17/2024, Vol. 25 Issue 1, p1-7. 7p.
Autor:
Ovcharenko, Dmitriy1 (AUTHOR) ovcharenko@altogen.com, Mukhin, Dmitry1 (AUTHOR), Ovcharenko, Galina1 (AUTHOR)
Publikováno v:
Pharmaceutics. Sep2024, Vol. 16 Issue 9, p1237. 28p.
Autor:
Pantziarka P; Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium; The George Pantziarka TP53 Trust, London KT1 2JP, UK. Electronic address: anticancer.org.uk@gmail.com., Verbaanderd C; Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium; Department of Pharmaceutical and Pharmacological Sciences, University of Leuven, Leuven, Belgium., Huys I; Department of Pharmaceutical and Pharmacological Sciences, University of Leuven, Leuven, Belgium., Bouche G; Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium., Meheus L; Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium.
Publikováno v:
Seminars in cancer biology [Semin Cancer Biol] 2021 Jan; Vol. 68, pp. 186-191. Date of Electronic Publication: 2020 Jan 23.
Autor:
Broes S; Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.; European Organisation for Research and Treatment of Cancer, Brussels, Belgium., Verbaanderd C; Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.; Anticancer Fund, Strombeek-Bever, Belgium., Casteels M; Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium., Lacombe D; European Organisation for Research and Treatment of Cancer, Brussels, Belgium., Huys I; Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Publikováno v:
Frontiers in medicine [Front Med (Lausanne)] 2020 Feb 11; Vol. 7, pp. 33. Date of Electronic Publication: 2020 Feb 11 (Print Publication: 2020).
Autor:
Verbaanderd C; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.; Anticancer Fund, Strombeek-Bever, Belgium., Rooman I; Anticancer Fund, Strombeek-Bever, Belgium.; Oncology Research Centre, Vrije Universiteit Brussel, Brussels, Belgium., Meheus L; Anticancer Fund, Strombeek-Bever, Belgium., Huys I; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Publikováno v:
Frontiers in pharmacology [Front Pharmacol] 2020 Jan 31; Vol. 10, pp. 1664. Date of Electronic Publication: 2020 Jan 31 (Print Publication: 2019).